|
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients |
Maryland |
Completed |
Multiple Sclerosis |
|
A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia |
Maryland* |
Completed |
Chronic Dysphagia, Multiple Sclerosis, Parkinson Disease |
|
Assessment of Patients With Multiple Sclerosis (MS) |
Maryland* |
Completed |
Herpesviridae Infection, HTLV-I Infection, Multiple Sclerosis, Tropical Spastic Paraparesis, Vasculitis |
|
Biomarkers in Multiple Sclerosis |
Maryland* |
Completed |
Multiple Sclerosis |
|
Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis |
Maryland* |
Completed |
Multiple Sclerosis |
|
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System |
Maryland* |
Recruiting |
Central Nervous System Disease, Multiple Sclerosis |
|
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) |
Maryland* |
Terminated |
Multiple Sclerosis |
|
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques |
Canada |
Enrolling by Invitation |
Multiple Sclerosis |
|
Effects of Stimulation Patterns of Deep Brain Stimulation |
Multiple U.S. Locations |
Enrolling by Invitation |
Parkinson Disease, Essential Tremor, Multiple Sclerosis |
|
Idebenone for Primary Progressive Multiple Sclerosis |
Maryland* |
Enrolling by Invitation |
Multiple Sclerosis, Primary Progressive Multiple Sclerosis |
